Science Translational Medicine: Scientists identify a way to significantly delay the return of the most aggressive brain tumor

Researchers from the United Kingdom and Spain have discovered that immediately after surgery to remove glioblastoma—the most aggressive and common malignant brain tumor in adults—there is a brief period during which the remaining cancer cells become far more vulnerable to treatment. The findings were published in Science Translational Medicine.

Current standard treatment involves surgical removal of the tumor, followed by chemotherapy and radiotherapy four to six weeks later. During this interval, however, residual cancer cells can infiltrate healthy brain tissue, allowing the tumor to almost inevitably recur.

The researchers found that surgery temporarily disrupts the blood-brain barrier, which normally prevents most drugs from entering the brain. This creates two short therapeutic windows for treatment: the first immediately after surgery and the second 48 to 72 hours later.

In experiments involving mice, scientists injected lipid nanoparticles loaded with the chemotherapy drug doxorubicin into the bloodstream. The nanoparticles selectively accumulated along the margins of the removed tumor—the area where recurrence most commonly begins—while showing minimal penetration into healthy brain tissue.

According to the researchers, a single injection administered during either of these therapeutic windows was enough to significantly delay tumor recurrence and improve disease control while causing only minimal side effects.

Although lipid nanoparticles are already widely used in medicine to deliver a variety of drugs, including cancer therapies, they have not previously demonstrated significant effectiveness against glioblastoma. The new findings suggest that the timing of drug delivery may be just as important as the treatment itself.

The results have so far been demonstrated only in animal studies. The next step will be clinical trials involving patients. If confirmed in humans, the approach could reshape the current treatment strategy for glioblastoma by targeting residual tumor cells before they have the opportunity to regrow.

Follow NEWS.am Medicine on Facebook and Twitter